A one-two punch with VO KOs CLL
- PMID: 31248874
- DOI: 10.1182/blood-2019-04-901116
A one-two punch with VO KOs CLL
Conflict of interest statement
Conflict-of-interest disclosure: S.C. received honoraria from Janssen and Pharmacyclics (nonpromotional education programs); had a consulting or advisory role for AbbVie, Celgene, Janssen, Novartis, Pharmacyclics, Astellas, and Astra Zeneca; received research funding (institutional and salary support) from AbbVie, Acerta, Celgene, Gilead, Janssen, Pharmacyclics, and Takeda; received travel, accommodations, and expenses from AbbVie, BeiGene, Celgene, Genentech, Janssen, and Pharmacyclics; is on the data safety monitoring committee for BeiGene; and provided expert advice for patent litigation in Canada and South Korea for Genentech.
Comment on
-
Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.Blood. 2019 Jun 27;133(26):2765-2775. doi: 10.1182/blood-2019-01-896290. Epub 2019 Mar 12. Blood. 2019. PMID: 30862645 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources

